214 related articles for article (PubMed ID: 28791875)
1. Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
Nadkarni A; McMorrow D; Patel C; Fowler R; Smith D
J Comp Eff Res; 2017 Nov; 6(8):671-682. PubMed ID: 28791875
[TBL] [Abstract][Full Text] [Related]
2. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
Schmier J; Ogden K; Nickman N; Halpern MT; Cifaldi M; Ganguli A; Bao Y; Garg V
Clin Ther; 2017 Aug; 39(8):1600-1617. PubMed ID: 28716293
[TBL] [Abstract][Full Text] [Related]
3. Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.
Holden SE; Currie CJ; Lennon M; Reynolds AV; Moots RJ
Clin Exp Rheumatol; 2016; 34(4):679-84. PubMed ID: 27191345
[TBL] [Abstract][Full Text] [Related]
4. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
6. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
7. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
Nadkarni A; McMorrow D; Fowler R; Smith D
J Comp Eff Res; 2017 Nov; 6(8):659-669. PubMed ID: 28791873
[TBL] [Abstract][Full Text] [Related]
8. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
9. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
10. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
11. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
[TBL] [Abstract][Full Text] [Related]
13. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
16. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
18. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
Ariza R; Van Walsem A; Canal C; Roldán C; Betegón L; Oyagüez I; Janssen K
Farm Hosp; 2014 Jul; 38(4):257-65. PubMed ID: 25137158
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
20. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs.
Moots RJ; Mays R; Stephens J; Tarallo M
Clin Exp Rheumatol; 2015; 33(5):737-45. PubMed ID: 26053198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]